Dermata Therapeutics, Inc. (DRMA)
Nasdaq · Healthcare · Biotechnology
$1.11+0.45%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $5.5M
- 52-week range
- $0.951 – $5.87
- 52-week change
- −79.46%
- EPS (trailing)
- −$4.39
Fiscal year to Dec 2025
- Net income
- −$7.6M
- Diluted EPS
- −$8.16
From the company’s annual report on SEC EDGAR.
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 9 employees · dermatarx.com